ASO Author Reflections: Who Benefits From Adjuvant PD-1 Inhibition? Navigating Time-Dependent Efficacy in Resected HCC.
APA
Guo B, Luo C, Zhang W (2026). ASO Author Reflections: Who Benefits From Adjuvant PD-1 Inhibition? Navigating Time-Dependent Efficacy in Resected HCC.. Annals of surgical oncology, 33(2), 1552-1553. https://doi.org/10.1245/s10434-025-18654-2
MLA
Guo B, et al.. "ASO Author Reflections: Who Benefits From Adjuvant PD-1 Inhibition? Navigating Time-Dependent Efficacy in Resected HCC.." Annals of surgical oncology, vol. 33, no. 2, 2026, pp. 1552-1553.
PMID
41145933
같은 제1저자의 인용 많은 논문 (5)
- Long-Term Survival and Beneficiaries of Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma.
- Advances in the combined treatment of solid tumors with nanodelivery systems based on engineered bacteria-TME modulation.
- Vessels encapsulating tumor clusters is associated with impaired efficacy of adjuvant immunotherapy in resected hepatocellular carcinoma.
- Deciphering the role of cathepsins in digestive system cancers: a Mendelian randomization study.
- Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma.